iA Global Asset Management Inc. Buys Shares of 12,393 Illumina, Inc. $ILMN

iA Global Asset Management Inc. bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the third quarter, Holdings Channel reports. The institutional investor bought 12,393 shares of the life sciences company’s stock, valued at approximately $1,177,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Empowered Funds LLC raised its stake in Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Illumina during the 2nd quarter worth approximately $621,000. Farther Finance Advisors LLC raised its position in shares of Illumina by 9.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 2,521 shares of the life sciences company’s stock valued at $241,000 after buying an additional 225 shares during the period. Park Avenue Securities LLC raised its position in shares of Illumina by 9.5% during the 2nd quarter. Park Avenue Securities LLC now owns 6,609 shares of the life sciences company’s stock valued at $631,000 after buying an additional 571 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Illumina by 199.5% in the second quarter. GAMMA Investing LLC now owns 2,465 shares of the life sciences company’s stock valued at $235,000 after acquiring an additional 1,642 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. This represents a 1.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Scott Gottlieb purchased 500 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was acquired at an average price of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 2.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ILMN. Robert W. Baird set a $109.00 target price on Illumina in a research note on Friday, October 31st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. JPMorgan Chase & Co. raised their price objective on Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Stifel Nicolaus upped their target price on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Six analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $124.47.

Illumina Price Performance

ILMN opened at $150.28 on Friday. The stock’s 50-day moving average price is $135.20 and its 200 day moving average price is $113.23. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53. The firm has a market cap of $22.96 billion, a price-to-earnings ratio of 33.70, a PEG ratio of 2.50 and a beta of 1.41. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.18. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.Illumina’s revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.